|
|
Post by babaoriley on Mar 27, 2014 22:43:11 GMT -5
|
|
|
|
Post by thekindaguyiyam on Mar 27, 2014 23:31:56 GMT -5
Bill oh! Really?
look at his focus as if he's reading a monitor. no emotion. bottom line according to this guy is that there will be no price movement upon acceptance because that's the way things are... along with because there is no partnership announcement prior to the ADCOM mnkd will fail with afrezza due to it being a drug that is inhaled.
Bill Oh Really?; should be more careful where he parks as he got locked out of his car due to a snow storm. He left his profession in his field of expertise to pursue writing BS for the fool. Is this really the best they can do? It makes me feel like this guy is a pawn who is about to be beheaded as an offering to the gods as a result of his unbelievable assertions.
Still holding all of my shares and all of my calls. No influence on my confidence of MNKD with Alfred saying "of course it works".
jmho
Iyam
|
|
|
|
Post by liane on Mar 28, 2014 5:07:43 GMT -5
Well that was painful to listen to. Very poor speaker. I wonder what short is paying him off. It's as if he had the list of short "talking points" and was just rattling them off. Pure garbage.
|
|
|
|
Post by savzak on Mar 28, 2014 7:08:37 GMT -5
I saw this guy on a Motley video in early to mid-February before the Chelsea PDUFA. He discussed three drugs with upcoming PDUFA dates. Chelsea and MannKind were two of them. I can't recall the third. He said that he believed all three would be approved, but he did opine that Afrezza was the closest call of the three.
I don't think this video is so bad. He's obviously not as enthused as we all are. And his concern over safety seems misplaced since there have been no safety indications at all. He does acknowledge the market potential of Afrezza as well as the fact that it "seems to" work better than the current alternatives.
The comment that seemed oddest to me was at the beginning, when he seems to say that the briefing documents may effectively end the question of what the FDA is interested in, and thus whether the drug will ultimately be approved.
|
|
